Kazuhiro Yamamoto*, Takeshi Ioroi*, Kazuaki Shinomiya†, Ayaka Yoshida*, Kenichi Harada‡, Masato Fujisawa‡, Tomohiro Omura*, Yasuaki Ikemi§, Shunsaku Nakagawa§, Atsushi Yonezawa§, Osamu Ogawa¶, Kazuo Matsubara§, Takuya Iwamoto#, Kohei Nishikawa**, Sayaka Hayashi††,
Daichi Tohara††, Yoji Murakami‡‡, Takanobu Motoshima‡‡, Hirofumi Jono††, Ikuko Yano*§
Oncology Research, Vol.29, No.1, pp. 11-23, 2021, DOI:10.3727/096504022X16418911579334
Abstract We evaluated the association of signal transducer and activator of transcription 3 (STAT3) polymorphisms with
the incidence of mammalian target of rapamycin (mTOR) inhibitor-induced interstitial lung disease (ILD) in
patients with renal cell carcinoma (RCC). We also used lung-derived cell lines to investigate the mechanisms
of this association. Japanese patients with metastatic RCC who were treated with mTOR inhibitors were genotyped for the STAT3 polymorphism, rs4796793 (−1697C/G). We evaluated the association of the STAT3 genotype with the incidence of ILD and therapeutic outcome. In the 57 patients included in the primary analysis, the
ILD rate… More >
Login
Register
